Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACO/ARO/AIO-18.1 rectal cancer organ preservation trial
2018-000876-14Phase 3Active
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Oct 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, oxaliplatin, capecitabine and folinic acid in rectal adenocarcinoma and locally advanced rectal cancer (LARC) (2 arms), sponsored by Universitätsklinikum Frankfurt. Primary endpoint: Organ preservation. Started Oct 2019; status: active.
02
Drugs
fluorouraciloxaliplatincapecitabinefolinic acid
03
Conditions
rectal adenocarcinomalocally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on 2018-000876-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000876-14.